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Abstract
The early diagnosis of congenital Chagas' disease is very important if infected newborns, whether
symptomatic or not, are to receive adequate treatment. This paper describes the complications
arising in the diagnosis of a newborn with fatal congenital Chagas' disease in Spain, a non-endemic
area where visceral leishmaniasis is present.
Introduction
Chagas' disease is endemic from the south of the United
States to southern Argentina and Chile, where it is mainly
transmitted by reduvid insects. The protozoan that causes
the disease – which has a wide range of clinical manifesta-
tions – is T. cruzi, a parasite that shows great genetic vari-
ation. Large numbers of protozoa are detected during the
acute phase of the disease, while numbers are much lower
during the chronic phase. However, it is during this latter
phase when the humoral immune response is patent.
Vertical or congenital transmission of T. cruzi is also pos-
sible. This route is associated with an infection rate of 0–
10%, depending on the geographical area in question.
Recent studies indicate the majority of children born to
infected mothers to be asymptomatic, although some 2–
10% present with severe respiratory distress, hepat-
osplenomegaly, myocarditis and meningoencephalitis
[1]. Without specific treatment, the mortality rate among
such children is high. Since the transmission of T. cruzi
during pregnancy cannot be prevented, early diagnosis in
newborns is essential so that appropriate etiological treat-
ment can be administered; such treatment can be 100%
effective. Since maternal IgG antibodies and excretion-
secretion antigens that stimulate IgM or IgA production
can cross the placenta [2], serological tests cannot discrim-
inate between infected and non-infected newborns. How-
ever, the presence of anti-T. cruzi antibodies in maternal
serum identifies mothers whose newborns are at risk of
having been infected [2]. Accordingly, to confirm the par-
asite infection, mobile T. cruzi trypomastigotes should be
sought microscopically in the cord blood or peripheral
blood of newborns after a concentration procedure (the
microhaematocrit test) [3].
Case presentation
A 37 year-old Argentine woman with a background of
bipolar disease attended an appointment for a fetal ultra-
sound scan during the third trimester of pregnancy at a
teaching hospital. The results revealed her unborn child to
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be suffering a 3–4 weeks delay in growth, unilateral ven-
triculomegaly, and signs of stress. Birth was induced at 34
weeks (delivery was by Caesarean section); the newborn
weighed 1130 g and was in a convulsive state. Physical
examination of the child revealed scant spontaneous
activity, moderate responses to stimuli, poor peripheral
perfusion, severe microcephaly, small palpebral slits, foci
of choroiditis, vitreous opacity, and hepatosplenomegaly.
Cranial ultrasonography revealed a left subependimal
hemorrhage and dilation of the occipital horns of the lat-
eral ventricles. A cranial computed tomography (CT) scan
confirmed the dilation of the lateral ventricles and
revealed colpocephaly and megacisterna magna. Electro-
encephalography indicated a low to moderate activity
voltage and discrete signs of dysrhythmia in the frontal
zone. Ultrasonography detected hypertrophy of the left
ventricle of the heart; systolic function was conserved. In
abdominal ultrasound scans the liver was hyperecho-
genic; moderate hepatosplenomegaly was also seen.
Blood tests revealed leukopenia, neutropenia and persist-
ent thrombocytopenia, hypoproteinemia, hyponatremia
and hypocalcemia, elevated non-conjugated bilirubin lev-
els, elevated concentrations of glutamyl oxaloacetic
transaminase, glutamyl pyruvic transaminase, gamma-
glutamyl transpeptidase and alkaline phosphatase. To
rule out a possible intrauterine infection or connatal sep-
sis, blood and cerebrospinal fluid (CSF) were cultured
with negative results. The latex agglutination test for Strep-
tococcus group B bacteria and the shell-vial test for cytome-
galovirus were performed on urine samples; all results
were negative. Serological tests ruled out TORCHES,
Epstein-Barr virus, parvovirus (B19), enterovirus and ade-
novirus infections. During the newborn's stay in the
intensive care unit, fever peaks were recorded. A lower uri-
nary tract infection caused by Escherichia coli was identi-
fied; treatment with ampicillin and cefotaxime was
administered. Newborn blood, urine, fecal and CSF sam-
ples were examined by the Centro Nacional de Microbiología
(CNM), a Reference Center for Infectious Diseases for the
Spanish Healthcare System, to test for viral infections and
toxoplasmosis; all tests were negative. Tests of samples of
maternal serum ruled out rubella, cytomegalovirus, syph-
ilis, toxoplasmosis and HIV; only anti-herpes IgG anti-
bodies were detected (IgM negative). The child died after
2 1/2 months of poor clinical progress during which no
response to symptomatic treatment was seen. Autopsy
revealed generalized nodular encephalitis. The entire cer-
ebral cortex showed inflammatory nodules around areas
of necrotic tissue (Fig. 1A). The cytoplasm of the mononu-
clear phagocytes in the cortex and brainstem showed
round structures compatible with Leishman-Donovan
bodies (Fig. 1B and 1C). The same structures were not
seen, however, in histological sections of the myocar-
dium, liver or spleen. Taking into account these results,
the post mortem diagnosis was leishmaniasis. To investi-
gate the possible route of Leishmania infection, the mother
and the rest of her family underwent serological tests for
this pathogen. A commercial indirect immunofluorescent
antibody test (IFAT) kit (Leishmania Spot IF, bioMérieux)
detected IgG anti-Leishmania  antibodies in the mother
and one of the child's two siblings (Table 1).
To confirm these latter results, sections of the child's
brain, spleen, liver and heart embedded in paraffin wax
were examined by the Parasitology Department of the
CNM. The serums of the family members (stored at -20°C
until use) were also analyzed. DNA was extracted from the
embedded tissues and from the child's serum, and PCR
was performed using oligonucleotides R221-R332 and
R223-R333 (Ln-PCR) [4] to test for Leishmania spp., and
Tcz1-Tcz2 [5] to test for Trypanosoma cruzi. The latter path-
ogen was detected in all newborn's samples examined,
but Leishmania was not detected. The T. cruzi genotype was
determined by PCR of miniexon and 24Sα rRNA genes
[6,7], Tc IId was identified. In addition, in-house IFAT
using L. infantum as antigen showed an absence of anti-
Leishmania  antibodies in all family members tested,
except for a doubtful positive result for one of the
deceased child's siblings. Further testing found no anti-
bodies to rk39 [8], a specific antigen of the Leishmania
donovani complex, in any family member. IgG anti-T. cruzi
antibodies were detected by IFAT and ELISA (using T. cruzi
Table 1: Detection of anti-Trypanosoma cruzi and anti-Leishmania antibodies in the family members of the deceased child.
T. cruzi tests Leishmania tests
In-housea ELISA In-houseb IFAT rk39-ELISAa In-houseb IFAT Commercialb IFAT
Mother 2.09 > 1/320 0.04 N 1/1280
Father 0.05 N 0.01 N N
Brother 1 2.10 1/320 0.07 ± 1/80 1/320
Brother 2 0.04 N 0.01 N N
Deceased child 1.89 > 1/320 0.03 N nd
NOTE. - aResults are expressed as absorbances. The cut-off in the T. cruzi ELISA test was 0.5, and 0.2 in the rk39 ELISA test.
bThe IFAT results show the serum dilutions in which fluorescent parasites were observed. The cut-off for T. cruzi was 1/40, and 1/80 for Leishmania. 
N = negative, ± = parasites observed with and without fluorescence, nd = not done.Cases Journal 2008, 1:302 http://www.casesjournal.com/content/1/1/302
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as antigen) in the mother and in the same sibling as above
– a clear marker of T. cruzi infection. Anti-T. cruzi antibod-
ies were also found in serum of the newborn (Table 1).
Discusion
In Spain, Chagas' disease is an emerging imported parasi-
tosis. In recent years, the population of immigrants from
areas where the disease is endemic has grown notably;
indeed, these citizens represent some 34% of the country's
entire immigrant population (1 735 025 are Latin Ameri-
cans) [9]. This situation has influenced legislation regard-
ing the selection of blood donors; thus since 2005
Spanish law requires all blood transfusion centers to per-
form validated testing to rule out T. cruzi infection on
individuals with epidemiological risk. However, no con-
sensus has been reached with respect to the monitoring of
pregnant women from endemic areas, and only some
Spanish regions (Valencia, Catalonia and Murcia) per-
form serological screening during pregnancy. To date, a
number of cases of congenital transmission have been
described, in which the administration of appropriate
Detection of Trypanosoma cruzi parasites in samples of the deceased child Figure 1
Detection of Trypanosoma cruzi parasites in samples of the deceased child. A and B, sections of cerebral cortex stained with 
hematoxylin and eosin, and C, brain stem stained with Giemsa stain. The magnification is shown in the lower right corner; C is 
digitally magnified. Arrows indicate: in A, an inflammatory nodule, in B, parasites in the cytoplasm, and in C the nucleus (N) and 
kinetoplast (K) of one of the amastigotes. D, Results of Tcz1-Tcz2 PCR (lanes 1 to 5) and Ln-PCR (lanes 6 to 10) from serum. 
Lanes 1 and 6, serum; lanes 2, 5, 7 and 10, negative controls; lanes 3 and 8, T. cruzi positive control; lanes 4 and 9, Leishmania 
positive control; M, molecular weight markers (PCR marker 50 – 2000 bp).
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treatment was associated with favorable clinical progress
[10,11].
The present paper describes a severe case of congenital
Chagas' disease that was diagnosed post mortem. This high-
lights the limitations of conventional microscopic and
serological analyses when the epidemiological back-
ground is not considered. Since information on the
mother's origin was not made available while the child
was alive, the possibility of Chagas' disease was not taken
into account, therefore the newborn was monitored fol-
lowing the normal Spanish protocols.
The post mortem detection of T. cruzi DNA in a serum sam-
ple from the newborn analyzed at the Parasitology
Department of the CNM indicates that parasites had been
circulating in the peripheral blood (Fig. 1D); a lack of
experience in microscopical diagnosis of trypomastigotes
probably explains why they were unnoticed in earlier
blood tests. On the other hand, as the tissue amastigotes
of T. cruzi are morphologically very similar to the Leishma-
nia  amastigotes, they can be confused in microscopic
examinations. With respect to immunodiagnosis,
although the conventional serology procedures for both
protozoa show good sensitivity and specificity in terms of
discriminating between infected and non-infected indi-
viduals, cross reactivity is a problem. The present data
show that the commercial IFAT kit used to test for anti-
Leishmania antibodies suffers this disadvantage (Table 1).
Therefore, the reliability of commercial serological kits for
the diagnosis of Chagas' disease and leishmaniasis should
be assessed in this new epidemiological context, espe-
cially since parasitological diagnosis is of low sensitivity
in the chronic phase of T. cruzi infection. It should be
remembered that the recombinant antigen rk39 shows no
cross reactivity with sera from patients with Chagas' dis-
ease [8], therefore the absence of anti-rk39 antibodies in
any of the newborn's family members confirms that what
were thought to be anti-Leishmania antibodies detected by
the commercial IFAT kit were a product of cross-reactivity.
Since in Spain, the immigrant population is exposed to
Leishmania infection, and given that cross reactivity can be
a problem in serological analyses, PCR might offer the
best way to discriminate between L. infantum and T. cruzi.
Indeed, from year 2002 to 2007, 100 newborns' blood
samples (whose mothers were seropositive to T. cruzi
infection) were examined by T. cruzi-PCR at the Parasitol-
ogy Department of CNM-ISCIII. It is important to high-
light that three new cases were PCR positive in the last year
(3/78).
Neither the detection of parasites in the placenta nor
maternal infection with any particular genotype are indi-
cators of congenital infection. However, it has been
reported that mothers who transmit the T. cruzi infection
commonly have high parasitaemia and show an associ-
ated reduction in γ-IFN production [12]. Although these
factors were not examined in the present mother, it is
probable that a state of immunodepression had been
favored by her bipolar disease, which in turn would have
favored a high parasite load and the infection of her fetus.
The post mortem microscopical detection of the parasite in
the child's brain tissue might explain the ultrasonography
and cranial CT findings. Although no amastigotes were
seen in the remaining tissues examined, the presence of T.
cruzi DNA in all the necropsy samples suggests that the
parasite was distributed all over the child's body, causing
the pathological alterations recorded. At monitoring
times during the first and second trimester, ultrasound
scans revealed no fetal abnormalities, suggesting that
intrauterine infection occurred during the third trimester.
Conclusion
In the absence of prognostic markers for the development
of the infection, a procedure involving i) the serological
screening of pregnant women from Latin America, ii) fetal
monitoring by ultrasonography, and iii) parasitological
diagnosis of the newborn, via direct microscopic observa-
tion and molecular tests, may contribute towards the early
detection of congenital T. cruzi infection in non-endemic
areas, allowing newborns to receive timely treatment.
Moreover, since reinfection is unlikely in Spain, providing
post-partum anti-parasite treatment to infected mothers
could help avoid further instances of vertical transmis-
sion.
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